Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation

Antiviral Research

Volumn 86, Issue 2, 2010, Pages 137-143

  Caso, Giuseppe ^a   Mileva, Izolda ^a   Mcnurlan, Margaret A ^a   Mynarcik, Dennis C ^a   Darras, Frank ^a   Gelato, Marie C ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adipogenesis; Adiponectin; HIV protease inhibitors; PPAR ; Preadipocyte

Indexed keywords

ADIPOCYTOKINE; ATAZANAVIR; CCAAT ENHANCER BINDING PROTEIN ALPHA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITONAVIR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSCRIPTION FACTOR AP 2;

ADIPOGENESIS; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPOATROPHY; MALE; PRIORITY JOURNAL; PROADIPOCYTE; SUBCUTANEOUS FAT;

ADIPOCYTES; ADIPONECTIN; ADULT; ANTI-HIV AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FATTY ACID-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PPAR GAMMA; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS;

EID: 77951299062     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.004     Document Type: Article

References (37)

1. Bastard J.P., Caron M., Vidal H., Jan V., Auclair M., Vigouroux C., Luboinski J., Laville M., Maachi M., Girard P.M., Rozenbaum W., Levan P., Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026-1031.
2. Becker S. Atazanavir: improving the HIV protease inhibitor class. Expert Rev. Anti. Infect. Ther. 2003, 1:403-413.
3. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
4. Caron M., Auclair M., Vigouroux C., Glorian M., Forest C., Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
5. Caron M., Vigouroux C., Bastard J.P., Capeau J. Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARgamma-dependent pathways. PPAR Res. 2009, 2009:507141.
6. Caso G., McNurlan M.A., McMillan N.D., Eremin O., Garlick P.J. Tumour cell growth in culture: dependence on arginine. Clin. Sci. (Lond.) 2004, 107:371-379.
7. Dowell P., Flexner C., Kwiterovich P.O., Lane M.D. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J. Biol. Chem. 2000, 275:41325-41332.
8. Fajas L., Schoonjans K., Gelman L., Kim J.B., Najib J., Martin G., Fruchart J.C., Briggs M., Spiegelman B.M., Auwerx J. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol. 1999, 19:5495-5503.
9. Gatti G., Di Biagio A., Casazza R., De Pascalis C., Bassetti M., Cruciani M., Vella S., Bassetti D. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999, 13:2083-2089.
10. Grigem S., Fischer-Posovszky P., Debatin K.M., Loizon E., Vidal H., Wabitsch M. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm. Metab. Res. 2005, 37:602-609.
11. Haerter G., Manfras B.J., Mueller M., Kern P., Trein A. Regression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004, 18:952-955.
12. Hauner H., Entenmann G., Wabitsch M., Gaillard D., Ailhaud G., Negrel R., Pfeiffer E.F. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J. Clin. Invest. 1989, 84:1663-1670.
13. Jain R.G., Furfine E.S., Pedneault L., White A.J., Lenhard J.M. Metabolic complications associated with antiretroviral therapy. Antivir. Res. 2001, 51:151-177.
14. Jan V., Cervera P., Maachi M., Baudrimont M., Kim M., Vidal H., Girard P.M., Levan P., Rozenbaum W., Lombès A., Capeau J., Bastard J.P. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir. Ther. 2004, 9:555-564.
15. Janderová L., McNeil M., Murrell A.N., Mynatt R.L., Smith S.R. Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obes. Res. 2003, 11:65-74.
16. Jemsek J.G., Arathoon E., Arlotti M., Perez C., Sosa N., Pokrovskiy V., Thiry A., Soccodato M., Noor M.A., Giordano M. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin. Infect. Dis. 2006, 42:273-280.
17. Jones S.P., Waitt C., Sutton R., Back D.J., Pirmohamed M. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008, 22:1293-1298.
18. Kim R.J., Wilson C.G., Wabitsch M., Lazar M.A., Steppan C.M. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006, 14:994-1002.
19. Koutkia P., Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu. Rev. Med. 2004, 55:303-317.
20. Lagathu C., Bastard J.P., Auclair M., Maachi M., Kornprobst M., Capeau J., Caron M. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir. Ther. 2004, 9:911-920.
21. Lagathu C., Kim M., Maachi M., Vigouroux C., Cervera P., Capeau J., Caron M., Bastard J.P. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005, 87:65-71.
22. Lenhard J.M., Furfine E.S., Jain R.G., Ittoop O., Orband-Miller L.A., Blanchard S.G., Paulik M.A., Weiel J.E. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antivir. Res. 2000, 47:121-129.
23. Lihn A.S., Richelsen B., Pedersen S.B., Haugaard S.B., Rathje G.S., Madsbad S., Andersen O. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am. J. Physiol. Endocrinol. Metab. 2003, 285:E1072-E1080.
24. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
25. Miller J., Carr A., Emery S., Law M., Mallal S., Baker D., Smith D., Kaldor J., Cooper D.A. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003, 4:293-301.
26. Möbius U., Lubach-Ruitman M., Castro-Frenzel B., Stoll M., Esser S., Voigt E., Christensen S., Rump J.A., Fätkenheuer G., Behrens G.M., Schmidt R.E. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J. Acquir. Immune Defic. Syndr. 2005, 39:174-180.
27. Mynarcik D.C., Combs T., McNurlan M.A., Scherer P.E., Komaroff E., Gelato M.C. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J. Acquir. Immune Defic. Syndr. 2002, 31:514-520.
28. Otto T.C., Lane M.D. Adipose development: from stem cell to adipocyte. Crit. Rev. Biochem. Mol. Biol. 2005, 40:229-242.
29. Roche R., Poizot-Martin I., Yazidi C.M., Compe E., Gastaut J.A., Torresani J., Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002, 16:13-20.
30. Rudich A., Ben-Romano R., Etzion S., Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol. Scand. 2005, 183:75-88.
31. Sension M., Andrade Neto J.L., Grinsztejn B., Molina J.M., Zavala I., González-Garciá J., Donnelly A., Phiri P., Ledesma E., McGrath D. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J. Acquir. Immune Defic. Syndr. 2009, 51:153-162.
32. Solas C., Gagnieu M.C., Ravaux I., Drogoul M.P., Lafeuillade A., Mokhtari S., Lacarelle B., Simon N. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther. Drug Monit. 2008, 30:670-673.
33. Sutinen J., Korsheninnikova E., Funahashi T., Matsuzawa Y., Nyman T., Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J. Clin. Endocrinol. Metab. 2003, 88:1907-1910.
34. Tchkonia T., Giorgadze N., Pirtskhalava T., Tchoukalova Y., Karagiannides I., Forse R.A., DePonte M., Stevenson M., Guo W., Han J., Waloga G., Lash T.L., Jensen M.D., Kirkland J.L. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002, 282:R1286-R1296.
35. Vernochet C., Azoulay S., Duval D., Guedj R., Cottrez F., Vidal H., Ailhaud G., Dani C. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J. Biol. Chem. 2005, 280:2238-2243.
36. Wise L.S., Green H. Participation of one isozyme of cytosolic glycerophosphate dehydrogenase in the adipose conversion of 3T3 cells. J. Biol. Chem. 1979, 254:273-275.
37. Zhang B., MacNaul K., Szalkowski D., Li Z., Berger J., Moller D.E. Inhibition of adipocyte differentiation by HIV protease inhibitors. J. Clin. Endocrinol. Metab. 1999, 84:4274-4277.